date:Oct 26, 2018
list of the drugs that have been impacted.
The agency began testing valsartan products for the substance NDMA after it learned that Zhejiang Huahai Pharmaceuticals found it in several batches of its medications. The FDA also began testing for another impurity, N-Nitrosodiethylamine, or NDEA, after it was identified in three lots of the drugs made by Torrent Pharmaceuticals. NDEA is also a suspected human carcinogen. Not all batches of these medications have been found to be contaminated.
The